Major Depressive Disorder With Subthreshold Bipolarity in the National Comorbidity Survey Replication
Publication: American Journal of Psychiatry
Abstract
Objective:
There is growing clinical and epidemiologic evidence that major mood disorders form a spectrum from major depressive disorder to pure mania. The authors examined the prevalence and clinical correlates of major depressive disorder with subthreshold bipolarity compared with pure major depressive disorder in the National Comorbidity Survey Replication (NCS-R).
Method:
The NCS-R is a nationally representative face-to-face household survey of the U.S. population conducted between February 2001, and April 2003. Lifetime history of mood disorders, symptoms, and clinical indicators of severity were collected using version 3.0 of the World Health Organization's Composite International Diagnostic Interview.
Results:
Nearly 40% of study participants with a history of major depressive disorder had a history of subthreshold hypo-mania. This subgroup had a younger age at onset, more episodes of depression, and higher rates of comorbidity than those without a history of hypomania and lower levels of clinical severity than those with bipolar II disorder.
Conclusions:
These findings demonstrate heterogeneity in major depressive disorder and support the validity of inclusion of subthreshold mania in the diagnostic classification. The broadening of criteria for bipolar disorder would have important implications for research and clinical practice.
Increasing evidence supports the existence of a spectrum of bipolar disorder far wider than acknowledged by current diagnostic nosology. While recent lifetime prevalence estimates indicate that 1% of the U.S. population meet DSM-IV criteria for bipolar I disorder and 1.1% for bipolar II disorder, recurrent hypomania without depression or recurrent subthreshold hypomania (with or without depression) was found in 2.4% of respondents in the National Comorbidity Survey Replication (1). These findings are consistent with those of other general population surveys conducted over the past two decades demonstrating the high prevalence of subthreshold bipolar symptoms and disorder based on a range of definitions (2–6) and underscore the importance of unrecognized bipolarity in the general population.
The substantial proportion of the bipolar spectrum that is undetected has been attributed to both the narrow diagnostic criteria for bipolar II disorder and the inherent difficulty in detecting milder forms of hypomania (7). This problem is potentially greatest for major depressive disorder, which may include heterogeneous conditions. Clinical studies indicate that 30%–55% of those with major depression may have symptoms of hypomania (8–13) and that those with subthreshold hypomania are less likely to respond adequately to usual treatments for major depression (14, 15). Investigations of community samples demonstrate that those with major depression and sub-threshold bipolar disorder have more frequent suicide attempts (2, 16), higher rates of bipolar disorder among family members (2, 6), and greater comorbidity with anxiety, impulse control, and substance use disorders (2, 4, 6) than those without subthreshold hypomania. Some of the most compelling evidence for the validity of characterizing subthreshold mania is the greater conversion rate to threshold-level bipolar disorder among adolescents with subthreshold mania followed prospectively over time (6). These findings provide strong support for the clinical significance of hypomania involving fewer symptoms or lasting for a shorter time than required for DSM-IV diagnosis.
Recognition of the full spectrum of bipolar disorders is dependent on identification of the most appropriate definitions for subthreshold manifestations. Previous descriptions by Akiskal and colleagues (7, 17, 18) of the “soft” bipolar spectrum have proposed broadening criteria for bipolar II disorder as well as creating a third bipolar category to more fully acknowledge cyclothymic and hyperthymic states, family history of bipolar disorder, temperament, and hypomanic episodes that occur during pharmacotherapy. However, empirical evidence for either treatment-induced mania (19) or a latent hypomanic temperament has not been forthcoming (20). Based on emerging evidence for a dimensional conceptualization of hypomanic symptoms, inclusion of a diagnostic specifier for “hidden” bipolarity in major depressive disorder has been proposed (21).
Using data from the National Comorbidity Survey Replication (NCS-R; 22), we examined the validity of distinguishing subthreshold hypomania symptoms in patients with major depression. We compared indices of clinical severity, family history, comorbidity patterns, and treatment utilization among patients with major depression with and without subthreshold hypomania. Particular focus was placed on comparisons between major depression with subthreshold hypomania, unrecognized by current nosology, and the two DSM-IV mood disorders for which clinical manifestations are most proximal: bipolar II disorder and unipolar major depressive disorder.
Method
NCS-R Sampling and Field Procedures
The NCS-R is a nationally representative face-to-face household survey of the prevalence and correlates of a wide range of DSM-IV mental disorders that was carried out between February 2001 and April 2003 (22, 23). The sampling frame was English-speaking adults age 18 and older, selected through a multistage clustered area probability design from the civilian household population of the continental United States. The NCS-R procedures were approved by the Human Subjects Committees of Harvard Medical School and the University of Michigan. A detailed description of the survey's procedures is available elsewhere (23).
The NCS-R interview was carried out in two parts. The part 1 interview was administered to a nationally representative household sample of 9,282 respondents (the response rate was 70.9%); informed consent was obtained from all participants prior to interview. Part 1 included the core mental disorders assessed in the survey along with a battery of sociodemographic variables. In an effort to reduce respondent burden and control study costs, part 2 was administered to 5,692 of the part 1 respondents, including all part 1 respondents with a lifetime core disorder plus a probability subsample of other respondents. The part 2 sample was weighted to adjust for differential probabilities of within-household selection, differential probabilities of selection from the part 1 sample into the part 2 sample based on part 1 responses, and discrepancies between the sample and the U.S. population on sociodemo-graphic and geographic factors assessed in the 2000 census. The part 2 sample was used for these analyses.
Mood Disorder Assessment
The NCS-R diagnoses are based on version 3.0 of the World Health Organization's Composite International Diagnostic Interview (CIDI; 24), a fully structured, lay-administered diagnostic interview. Mood disorders (bipolar I disorder, bipolar II disorder, and unipolar depression) were diagnosed following the DSM-IV criteria, with the exception of the requirement that symptoms not meet the criteria for a mixed episode (criterion C for mania or hypomania and criterion B for major depressive episode). Criteria for subthreshold hypomania included the presence of at least one of the screening questions for mania (1): “Some people have periods lasting several days or longer when they feel much more excited and full of energy than usual. Their minds go too fast. They talk a lot. They are very restless or unable to sit still and they sometimes do things that are unusual for them, such as driving too fast or spending too much money. Have you ever had a period like this lasting several days or longer?” or “Have you ever had a period lasting several days or longer when most of the time you were so irritable that you either started arguments, shouted at people, or hit people?” and failure to meet the full diagnostic criteria for hypomania. If respondents endorse either of these questions, the entire mania module of the CIDI is administered and they are queried about 15 symptoms of mania; those who endorse three or more symptoms are asked about the duration, age at onset, recurrence, frequency, severity, and impairment.
In this study, we characterized those with major depressive disorder according to the presence of the mania spectrum as follows: 1) major depressive disorder with mania (bipolar I disorder); 2) major depressive disorder with hypomania (bipolar II disorder); 3) major depressive disorder with subthreshold hypomania, as defined above; and 4) major depressive disorder alone. These categories and their corresponding definitions are presented in Table 1. All cases in which there were plausible organic causes for these diagnoses were excluded. Clinical reappraisal interviews for bipolar disorders using the lifetime nonpatient version of the Structured Clinical Interview for DSM-IV (SCID; 25) were conducted with a probability subsample of 50 NCS-R respondents. CIDI cases were oversampled and the data weighted for this oversampling. As described in more detail elsewhere (26), concordance between the CIDI and the SCID was good for a diagnosis of bipolar I or bipolar II disorder (kappa=0.69), with sensitivity of 0.87, a specificity of 0.99, and an area under the receiver operating characteristic curve of 0.93. Concordance between the CIDI and the SCID was higher for bipolar I disorder (0.88) than for bipolar II disorder (0.50), but the McNemar test was consistently not significant, indicating that CIDI prevalence estimates were unbiased in relation to SCID prevalence estimates.
| Subgroup | DSM Disorder | Definition |
|---|---|---|
| Major depressive disorder with mania | Bipolar I disorder | Bipolar I disorder |
| Major depressive disorder with hypomania | Bipolar II disorder | Bipolar II disorder |
| Major depressive episode (with hypomania) | Major depressive episode with hypomania (without impairment) | |
| Major depressive disorder with subthreshold hypomania | Major depressive episode (with subthreshold hypomania) | Major depressive episode diagnosis and yes to either of the two mania screening questions (mania and irritability) |
| Major depressive disorder only | Major depressive episode | Major depressive episode diagnosis and no to both of the two mania screening questions (mania and irritability) |
Age at onset, age at offset, and number of episodes of manic or hypomanic episodes and major depression were assessed using retrospective self-reports at the syndrome level. Course of illness was also assessed retrospectively by asking respondents to estimate the number of years in which they had at least one episode of mania or hypomania and the number of years in which they had an episode of major depression.
Symptom severity was assessed in 12-month cases using a self-report version of the Young Mania Rating Scale (YMRS; 27) for mania or hypomania and the Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR; 28) for major depression. The YMRS was based on a fully structured respondent report version developed for parent reports (29). Severity was assessed for the month in the past year when symptoms of either mania or depression were most severe. Standard YMRS and QIDS-SR cutoff points were used to define episodes as severe (including the original YMRS and QIDS-SR ratings of very severe, with scores ≥25 on the YMRS and ≥16 on the QIDS-SR), moderate (YMRS scores, 15–24; QIDS-SR scores, 11–15), mild (YMRS scores, 9–14; QIDSSR scores, 6–10), or not clinically significant (YMRS scores, 0–8; QIDS-SR scores, 0–5). We did not collect data on differences in the accuracy of recall for the 12 months used in this study compared with those of the QIDS-SR (30 days) and the revised YMRS (7 days).
Role impairment in 12-month cases was assessed using the Sheehan Disability Scale (30). As with the YMRS and the QIDSSR, the Sheehan Disability Scale asks respondents to focus on the month in the past year when their manic, hypomanic, or major depressive symptoms were most severe. Respondents rated the degree to which the condition interfered with their home management, work, social life, and personal relationships using a visual analogue scale ranging from 0 to 10 (none=0, mild=1–3, moderate=4–6, severe=7–10).
Other Assessments
We also assessed anxiety disorders, impulse control disorders, and substance use disorders using the CIDI and based on DSMIV criteria. Organic exclusion rules and diagnostic hierarchy rules were used in making all diagnoses. As detailed elsewhere (31, 32), blinded clinical reappraisal interviews using the nonpatient version of the SCID with a probability subsample of NCS-R respondents found generally good concordance between CIDI and DSM-IV diagnoses of anxiety, mood, and substance use disorders with independent clinical assessments. Diagnoses of impulse control disorders were not validated, as the SCID clinical reappraisal interviews did not include an assessment of these disorders.
Lifetime and 12-month treatment by health care professionals (including psychiatrists, other mental health professionals, and general medical providers), human services professionals, and complementary or alternative medicine providers was assessed by self-report. Information concerning mania in family members was collected in the mania section of the CIDI, and information about depression in family members was gathered only for the respondent's mother and father in the childhood section of the CIDI. Lifetime suicide attempts were assessed using the suicidality module of the CIDI.
Statistical Analyses
Because of the weighting and clustering used in the NCS-R design, all statistical analyses were performed using the Taylor series linearization method (33), a design-based method implemented using SUDAAN, version 10 (RTI International, Research Triangle Park, N.C.). Significance tests of sets of coefficients were performed using Wald chi-square tests based on design-corrected coefficient variance-covariance matrices. Statistical significance was evaluated using a two-sided design with alpha set at 0.05. Controlling for respondent age and sex, linear regression was used to study the association between continuous outcomes (age at onset of mood disorders) and bipolar groups. Subgroup comparisons included major depression with mania versus hypomania versus subthreshold hypomania versus major depression alone. Logistic regression analyses were used to assess the associations between dichotomous outcomes and bipolar groups while controlling for age and sex.
Results
Table 2 presents the lifetime and 12-month prevalence rates for bipolar and unipolar mood disorders. When considered together, bipolar spectrum conditions were nearly as frequent as unipolar major depression without sub-threshold hypomania. The lifetime prevalence of major depression with subthreshold hypomania was 6.7%.
| Subgroup | Lifetime Prevalence | 12-Month Prevalence | ||
|---|---|---|---|---|
| % | SE | % | SE | |
| Major depressive disorder with mania | 0.7 | 0.1 | 0.3 | 0.1 |
| Major depressive disorder with hypomania | 1.6 | 0.2 | 0.8 | 0.1 |
| Major depressive disorder with subthreshold hypomania | 6.7 | 0.0 | 2.2 | 1.9 |
| Major depressive disorder only | 10.2 | 0.4 | 5.4 | 0.3 |
Information concerning clinical correlates of the mood disorder categories is presented in Table 3. Individuals with bipolar II disorder were more likely than those with major depression plus subthreshold hypomania to have been treated for mood disorders over their lifetime as well as within the past 12 months, but no treatment differences were observed between the latter subgroup and the major depression alone subgroup. Compared to those with major depression alone, however, those with major depression with subthreshold hypomania had greater rates of comorbidity with anxiety, substance use disorders, and behavioral problems. In comparison to respondents with bipolar II disorder, those with major depression with sub-threshold hypomania had lower comorbidity. The proportion of respondents with major depression with sub-threshold hypomania who had suicide attempts (41%) fell between that of the bipolar II subgroup (50%) and that of the major depression alone subgroup (31%). However, these differences were not statistically significant.
| Measure | Major Depression With Mania | Major Depression With Hypomania | Major Depression With Subthreshold Hypomania | Major Depression Only | Major Depression With Hypomania vs. Major Depression With Subthreshold Hypomania | Major Depression With Subthreshold Hypomania vs. Major Depression Only | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % | SE | % | SE | % | SE | % | SE | Odds Ratio | 95% CI | Odds Ratio | 95% CI | |
| Treatment for mood disorders | ||||||||||||
| Lifetime | 86.2 | 3.3 | 81.2 | 3.9 | 64.9 | 2.4 | 64.8 | 1.8 | 2.4* | 1.4–4.0 | 1.0 | 0.8–1.4 |
| Past 12 months | 67.7 | 8.8 | 46.3 | 5.4 | 38.8 | 3.9 | 38.3 | 2.3 | 1.7* | 1.2–2.4 | 1.2 | 0.9–1.5 |
| Comorbidity disorders (lifetime) | ||||||||||||
| Anxiety | 87.1 | 4.8 | 82.6 | 3.3 | 72.2 | 2.8 | 52.6 | 1.7 | 1.9* | 1.2–3.0 | 2.3* | 1.8–3.0 |
| Substance use | 63.9 | 4.6 | 41.8 | 3.7 | 35.3 | 2.3 | 18.0 | 1.5 | 1.4 | 1.0–2.0 | 2.3* | 1.7–3.1 |
| Behavioral problem | 69.0 | 5.5 | 50.4 | 5.1 | 41.1 | 2.1 | 19.2 | 1.0 | 1.7* | 1.1–2.6 | 2.3* | 1.8–2.9 |
| Suicide attempts (lifetime) | 66.1 | 7.1 | 50.2 | 6.7 | 40.7 | 3.3 | 31.2 | 3.2 | 1.5 | 0.9–2.7 | 1.4 | 1.0–2.1 |
| Role impairment indicated on the Sheehan Disability Scale (past 12 months) | ||||||||||||
| Severe | 94.3 | 3.8 | 91.9 | 3.8 | 67.1 | 4.0 | 61.5 | 2.3 | 5.6a* | 2.0–16.2 | 1.3a | 0.9–1.9 |
| Moderate | 5.7 | 3.8 | 7.0 | 3.6 | 24.7 | 3.7 | 27.6 | 2.2 | ||||
| Mild | NA | NA | 1.1 | 1.2 | 6.2 | 1.8 | 7.8 | 1.3 | ||||
| None | NA | NA | NA | NA | 2.0 | 1.1 | 3.1 | 0.8 | ||||
a
Respondents with severe symptoms compared with all others.
*p<0.05.
Examination of clinical correlates within the bipolar spectrum (Table 4) reveals that bipolar II disorder is associated with a fivefold higher risk of having a severe score on the YMRS compared to major depression with subthreshold hypomania, but no difference was observed when the categories of moderate and severe were collapsed. Individuals with major depression with subthreshold hypomania also were less likely to have been treated for manic symptoms over their lifetime or within the past 12 months. No difference was observed between these two conditions for family history of mania.
| Measure | Major Depression With Mania | Major Depression With Hypomania | Major Depression With Subthreshold Hypomania | Major Depression Only | Major Depression With Hypomania Vs. Major Depression With Subthreshold Hypomania | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| % | SE | % | SE | % | SE | % | SE | Odds Ratio | 95% CI | |
| Treatment for mania | ||||||||||
| Lifetime | 64.1 | 5.2 | 59.7 | 4.1 | 5.6 | 1.3 | NA | NA | 25.8* | 13.3–50.1 |
| Past 12 months | 44.8 | 10.1 | 36.0 | 5.0 | 12.5 | 3.3 | NA | NA | 4.0* | 1.7–9.3 |
| Young Mania Rating Scale (past 12 months) | ||||||||||
| Severe | 84.8 | 7.4 | 53.3 | 8.0 | 19.8 | 8.0 | NA | NA | 5.0a* | 1.4–18.2 |
| Moderate | 12.4 | 7.0 | 27.8 | 7.4 | 62.2 | 9.7 | NA | NA | ||
| Mild | 2.8 | 2.8 | 13.7 | 5.0 | 6.6 | 4.8 | NA | NA | ||
| None | 0.0 | 0.0 | 5.2 | 3.1 | 11.4 | 7.6 | NA | NA | ||
| Mania in family members | 70.4 | 5.6 | 67.8 | 3.9 | 76.0 | 5.8 | NA | NA | 0.7 | 0.3–1.4 |
a
Respondents with severe symptoms compared with all others.
*p<0.05.
Clinical correlates related to depression are presented in Table 5. Individuals with bipolar II disorder had significantly more severe depressive symptoms and more episodes of depression than those with major depression with subthreshold hypomania and were more likely to have been treated for depression over their lifetime. Those with major depression with subthreshold hypomania did not differ from those in the major depression only subgroup in severity of depressive symptoms, treatment of depression, or family history of depression. However, those with major depression with subthreshold hypomania had significantly more episodes of depression than those with major depression alone.
| Measure | Major Depression With Mania | Major Depression With Hypomania | Major Depression With Subthreshold Hypomania | Major Depression Only | Major Depression With Hypomania vs. Major Depression With Subthreshold Hypomania | Major Depression With Subthreshold Hypomania vs. Major Depression Only | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % | SE | % | SE | % | SE | % | SE | Odds Ratio | 95% CI | Odds Ratio | 95% CI | |
| Treatment for depression | ||||||||||||
| Lifetime | 86.2 | 3.3 | 77.4 | 4.5 | 64.9 | 2.4 | 64.8 | 1.8 | 1.8* | 1.1–3.1 | 1.1 | 0.8–1.4 |
| Past 12 months | 63.3 | 9.1 | 42.8 | 5.4 | 36.1 | 4.0 | 38.3 | 2.3 | 1.3 | 0.8–2.3 | 0.9 | 0.6–1.4 |
| Number of episodes of depression | ||||||||||||
| >5 | 72.0 | 4.9 | 60.2 | 5.4 | 39.6 | 1.9 | 25.6 | 1.6 | 2.3a* | 1.5–3.7 | 1.9a* | 1.5–2.4 |
| 2–5 | 23.3 | 3.9 | 25.1 | 3.5 | 41.3 | 2.2 | 39.3 | 2.0 | ||||
| ≤1 | 4.7 | 2.2 | 14.7 | 3.3 | 19.1 | 1.7 | 35.1 | 1.8 | ||||
| Quick Inventory of Depressive Symptoms (past 12 months) | ||||||||||||
| Severe | 72.4 | 10.0 | 73.8 | 7.5 | 54.1 | 3.5 | 51.7 | 2.1 | 2.4b* | 1.1–5.5 | 1.1b | 0.8–1.6 |
| Moderate | 20.5 | 9.5 | 26.2 | 7.5 | 36.6 | 3.4 | 36.9 | 2.0 | ||||
| Mild | 7.1 | 5.1 | 0.0 | 0.0 | 8.6 | 1.8 | 9.3 | 1.5 | ||||
| None | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.7 | 2.1 | 0.8 | ||||
| Depression in family members | 31.6 | 6.6 | 28.3 | 4.7 | 20.0 | 1.7 | 16.8 | 1.5 | 1.7 | 1.0–2.8 | 1.1 | 0.8–1.5 |
a
Respondents with more than five episodes compared with all others.
b
Respondents with severe symptoms compared with all others.
*p<0.05.
Figure 1 shows the mean age at onset of mania or hypomania and depression by bipolar spectrum subgroup. Major depression with subthreshold hypomania has an earlier age at onset than major depression alone and, in turn, a later age at onset than major depression with hypo-mania (bipolar II disorder). No differences were observed in age at onset of mania or hypomania and age at onset of depression between the major depression with hypomania subgroup and the major depression with subthreshold hypomania subgroup. The major depression with sub-threshold hypomania subgroup had a younger age at first onset of depression than did the major depression alone subgroup.
FIGURE 1. Mean Age at Onset of Mood Disorder, Mania or Hypomania, and Depression, by Mood Disorder Subgroupa
aError bars indicate 95% confidence intervals.
Discussion
Converging evidence from clinical and epidemiologic studies suggests that the current diagnostic criteria for bipolar II disorder fail to include milder but clinically significant bipolar syndromes and that a significant percentage of these conditions are diagnosed by default as unipolar major depression (6, 16). Using data from a nationally representative sample, we examined the validity of characterizing subthreshold bipolarity as a source of heterogeneity in major depressive disorder (6). Our principal aims were to estimate the prevalence of these categories of the bipolar spectrum and to compare the clinical characteristics of major depression with subthreshold hypomania to other bipolar disorders as well as to major depression alone.
Application of these categories revealed considerable diversity in the clinical manifestations of mood disorders and indicated that bipolar spectrum disorders occur almost as frequently as “pure” unipolar depression. However, the question of perhaps greatest importance to mood disorder research and clinical practice concerns the appropriateness of diagnosing major depression in individuals who also have subthreshold hypomania. This mood disorder subtype represents 39% of all cases of uni-polar major depression in the general population, and it was not found to differ from depression alone in terms of lifetime or 12-month treatment for mood disorders. While these findings are consistent with past research demonstrating that subthreshold hypomania is often subsumed under the category of unipolar depression (8, 9, 11–13, 16, 18), important differences were nonetheless observed in the clinical characteristics of these categories. Individuals with major depression and subthreshold hypomania had a younger onset age, greater rates of comorbidity, more episodes of depression, and a trend toward more suicide attempts compared to individuals with major depression alone. Considered jointly with reported differences in response to pharmacotherapy between these forms of mood disorder (15, 21), these findings underscore the heterogeneity of major depression and support the notion that a critical reappraisal of diagnostic criteria for mood disorders is warranted.
Differences were also observed for markers of clinical severity or history when comparing individuals with major depression and subthreshold hypomania and those meeting criteria for bipolar II disorder. However, these findings refiect the greater general illness severity in bipolar II disorder rather than differences in the basic expression of depressive or hypomanic syndromes. Perhaps the most convincing evidence for inclusion of the concept of subthreshold hypomania is the finding that a family history of mania is as common among those with subthreshold hypomania as those with mania/hypomania. Although the family history was based on respondent report, it is unlikely that there would be differential bias by the various mania or hypomania subgroups. As these differences are quantitative in nature, they are consistent with a conceptualization of depression with subthreshold hypomania as a milder manifestation of bipolar disorder as described nearly a century ago (34), the pertinence of which has been reemphasized since the introduction of modern diagnostic systems (8, 35). The inclusion of sub-threshold hypomania among those with major depression in the diagnosis of bipolar disorders would have a far-reaching impact on a number of scientific disciplines, ranging from descriptive and analytic epidemiology to genetic research, whose progress depends on the validity of mood disorder phenotypes. Most importantly, such an expansion of the bipolar concept would likely lead to important changes in the treatment of patients who are undiagnosed or misdiagnosed despite elevated morbidity and mortality rates (36, 37).
These findings also have important clinical implications for the evaluation of mood disorders. If there is a substantial group of individuals with major depression who have hidden bipolarity, it would be critical to include careful evaluation of a history of hypomanic symptoms and a family history of mania, as proposed by the addition of a diagnostic specifier for subthreshold bipolarity in the diagnostic category of major depression (21). Despite the widespread clinical belief that antidepressants may trigger bipolar symptoms in susceptible individuals, empirical evidence is lacking (19). However, the addition of a mood stabilizer after response to antidepressant treatment may be beneficial in those who manifest sub-threshold bipolarity (38).
These results provide the first comparisons of the prevalence and clinical correlates of bipolar II disorder, major depression with subthreshold hypomania, and major depression alone in a nationally representative U.S. sample. The high frequency of subthreshold hypo-mania among those with major depression confirm the findings of a population-based study of young adults that also revealed that approximately 40% of those with major depression may manifest bipolar disorder (6). Some limitations of this study should be considered in interpreting the findings. The use of the fully structured, lay-administered CIDI precluded the collection of information on the full spectrum of expression of bipolar disorder proposed in recent studies (7, 16, 39). Although we could not modify the thresholds for some of the diagnostic criteria for mania and depression, our definition of subthreshold bipolar disorder is still more restrictive than the definitions proposed by clinical researchers. Therefore, our prevalence estimate of subthreshold bipolar disorder is likely to underestimate bipolar spectrum disorder in the population. Although the clinical reappraisal study (26) found good concordance of CIDI diagnoses with blinded clinical diagnoses based on the SCID, concordance was lower for bipolar II disorder and subthreshold bipolar disorder than for bipolar I disorder. The less flexible nature of the CIDI in comparison to clinical interviews could also have led to overestimation of comorbidity and potentially influenced clinical severity markers. Differences between the 1-year recall period of the symptom scales used in the present study and those for which the scales were standardized diminish the comparability of the present findings with those of previous clinical samples. In addition, the prevalence of mania in family members was not assessed in all groups. Finally, although the prevalence of bipolar disorder would be expected to increase if diagnostic criteria were expanded to include major depression with subthreshold mania, there would not be an increase in the overall prevalence of mood disorders because there would be a concomitant decrease in the rates of major depression. This risk should be examined critically but weighed against prospective evidence that youths with major depressive episodes plus subthreshold mania have a high probability of conversion to bipolar I disorder (6) and that milder manifestations of the bipolar spectrum can be distinguished from major depression in severity, course, and comorbidity.
Footnotes
Received July 19, 2009; revisions received Feb. 1 and March 26, 2010; accepted April 5, 2010
The views and opinions expressed in this article are those of the authors and should not be construed to represent the views of any of the sponsoring organizations or agencies or the U.S. government.
References
1.
Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC: Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64:543–552
2.
Angst J, Gamma A, Benazzi F, Ajdacic V, Eich D, Rössler W: Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders, and hypomania. J Affect Disord 2003; 73:133–146
3.
Lewinsohn PM, Klein DN, Seeley JR: Bipolar disorders in a community sample of older adolescents: prevalence, phenomenology, comorbidity, and course. J Am Acad Child Adolesc Psychiatry 1995; 34:454–463
4.
Merikangas KR, Herrell R, Swendsen J, Rössler W, Ajdacic-Gross V, Angst J: Specificity of bipolar spectrum conditions in the comorbidity of mood and substance use disorders: results from the Zurich cohort study. Arch Gen Psychiatry 2008; 65:47–52
5.
Szadoczky E, Papp Z, Vitrai J, Rihmer Z, Furedi J: The prevalence of major depressive and bipolar disorders in Hungary: results from a national epidemiologic survey. J Affect Disord 1998; 50:153–162
6.
Zimmermann P, Brückl T, Nocon A, Pfister H, Lieb R, Wittchen HU, Holsboer F, Angst J: Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity. Arch Gen Psychiatry 2009; 66:1341–1352
7.
Akiskal HS, Bourgeois ML, Angst J, Post R, Moller H, Hirschfeld R: Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord 2000; 59(suppl 1):S5–S30
8.
Akiskal HS, Mallya G: Criteria for the “soft” bipolar spectrum: treatment implications. Psychopharmacol Bull 1987; 23:68–73
9.
Benazzi F: Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice. J Affect Disord 1997; 46:73–77
10.
Cassano GB, Savino M, Perugi G, Musetti L, Akiskal HS: Major depressive episode: unipolar and bipolar II. Encephale 1992; 18(spec no 1):15–18
11.
Hantouche EG, Akiskal HS, Lancrenon S, Allilaire JF, Sechter D, Azorin JM, Bourgeois M, Fraud JP, Châtenet-Duchêne L: Systematic clinical methodology for validating bipolar-II disorder: data in mid-stream from a French national multi-site study (EPIDEP). J Affect Disord 1998; 50:163–173
12.
Koukopoulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L: Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol 1980; 13:156–167
13.
Manning JS, Haykal RF, Connor PD, Akiskal HS: On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally. Compr Psychiatry 1997; 38:102–108
14.
Seemüller F, Severus E, Möller H-J, Riedel M: Antidepressants and suicidality in younger adults: is bipolar illness the missing link? Acta Psychiatr Scand 2009; 119:166–167
15.
Keck PE, Kessler RC, Ross R: Clinical and economic effects of unrecognized or inadequately treated bipolar disorder. J Psychiatr Pract 2008; 14(suppl 2):31–38
16.
Judd LL, Akiskal HS: The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003; 73:123–131
17.
Akiskal HS: The bipolar spectrum: new concepts in classification and diagnosis, in Psychiatry Update: The American Psychiatric Association Annual Review. Edited by, Grinspoon L. Washington, DC, American Psychiatric Press, 1983, pp 271–292
18.
Cassano GB, Akiskal HS, Savino M, Musetti L, Perugi G: Proposed subtypes of bipolar II and related disorders: with hypo-manic episodes (or cyclothymia) and with hyperthymic temperament. J Affect Disord 1992; 26:127–140
19.
Licht RW, Gijsman H, Nolen WA, Angst J: Are antidepressants safe in the treatment of bipolar depression? a critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatr Scand 2008; 118:337–346
20.
Meyer TD, Keller F: Is there evidence for a latent class called “hypomanic temperament”? J Affect Disord 2003; 75:259–267
21.
Angst J: The bipolar spectrum. Br J Psychiatry 2007; 190:189–191
22.
Kessler RC, Merikangas KR: The National Comorbidity Survey Replication (NCS-R): background and aims. Int J Methods Psychiatr Res 2004; 13:60–68
23.
Kessler RC, Berglund P, Chiu WT, Demler O, Heeringa S, Hiripi E, Jin R, Pennell BE, Walters EE, Zaslavsky A, Zheng H: The US National Comorbidity Survey Replication (NCS-R): design and field procedures. Int J Methods Psychiatr Res 2004; 13:69–92
24.
Kessler RC, Ustün TB: The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res 2004; 13:93–121
25.
First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version, Non-Patient Edition (SCID-I/NP). New York, New York State Psychiatric Institute, Biometrics Research, 2002
26.
Kessler RC, Akiskal HS, Angst J, Guyer M, Hirschfeld RM, Merikangas KR, Stang PE: Validity of the assessment of bipolar spectrum disorders in the World Health Organization CIDI 3.0. J Affect Disord 2006; 96:259–269
27.
Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978; 133:429–435
28.
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB: The 16-Item Quick Inventory of Depres-sive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54:573–583
29.
Gracious BL, Youngstrom EA, Findling RL, Calabrese JR: Discriminative validity of a parent version of the Young Mania Rating Scale. J Am Acad Child Adol Psychiatry 2002; 41:1350–1359
30.
Leon AC, Olfson M, Portera L, Farber L, Sheehan DV: Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 1997; 27:93–105
31.
Kessler RC, Abelson J, Demler O, Escobar JI, Gibbon M, Guyer ME, Howes MJ, Jin R, Vega WA, Walters EE, Wang P, Zaslavsky A, Zheng H: Clinical calibration of DSM-IV diagnoses in the World Mental Health (WMH) version of the World Health Organization (WHO) Composite International Diagnostic Interview (WMHCIDI). Int J Methods Psychiatr Res 2004; 13:122–139
32.
Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distributions of DSMIV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593–602
33.
Wolter K: Introduction to Variance Estimation. New York, Springer-Verlag, 1985
34.
Kraepelin E: Manic-Depressive Insanity and Significance of Hypomanic Switches in Unipolar Melancholic Paranoia. Edinburgh, ES Livingstone, 1899
35.
Angst J, Frey R, Lohmeyer B, Zerbin-Rudin E: Bipolar manic-depressive psychoses: results of a genetic investigation. Hum Genet 1980; 55:237–254
36.
Hirschfeld RM, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F, Endicott J, Froom J, Goldstein M, Gorman JM, Marek RG, Maurer TA, Meyer R, Phillips K, Ross J, Schwenk TL, Sharfstein SS, Thase ME, Wyatt RJ: The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997; 277:333–340
37.
Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM: The National Depressive and Manic-Depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994; 31:281–294
38.
Licht RW, Vestergaard P, Brodersen A: Long-term outcome of patients with bipolar disorder commenced on lithium prophylaxis during hospitalization: a complete 15-year register-based follow-up. Bipolar Disord 2008; 10:79–86
39.
Akiskal HS, Benazzi F: Optimizing the detection of bipolar II disorder in outpatient private practice: toward a systematization of clinical diagnostic wisdom. J Clin Psychiatry 2005; 66:914–921
Information & Authors
Information
Published In
History
Received: 19 July 2009
Revision received: 1 February 2010
Revision received: 26 March 2010
Accepted: 5 April 2010
Published online: 1 October 2010
Published in print: October 2010
Authors
Funding Information
Dr. Kessler has served in an advisory or consulting capacity for Eli Lilly, GlaxoSmithKline, Kaiser Permanente, Pfizer, Sanofi-Aventis, Shire, and Wyeth-Ayerst and has received research support for epidemiological studies from Bristol-Myers Squibb, Eli Lilly, GlaxoSmith-Kline, Johnson & Johnson Pharmaceuticals, Ortho-McNeil, Pfizer, and Sanofi-Aventis. Dr. Angst has served in advisory or speaking capacities for AstraZeneca, Eli Lilly, Janssen Cilag, and Sanofi-Aventis.The National Comorbidity Survey Replication was supported by NIMH grant U01-MH60220 with supplemental support from the National Institute of Drug Abuse; the Substance Abuse and Mental Health Services Administration; grant 044708 from the Robert Wood Johnson Foundation; and the John W. Alden Trust. Manuscript preparation was supported by NIMH's Intramural Research Program (for Ms. Cui and Drs. Cravchik, Rothen, and Merikangas) and an ATIP award (to Dr. Swendsen) from the French National Center for Scientific Research.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).